Citations

Clear

3030 citation(s) found for "Susan, M".

Abstract 20967: Outcomes and Prevalence of Migraines in Patients With Spontaneous Coronary Artery Dissections: A Cohort Study
Kok, Susan N., Cutrer, F. Michael , Gulati, Rajiv , Best, Patricia J.M. , Hayes, Sharonne N. , Tweet, Marysia S.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 136 | Issue: suppl_1 | Pages: No page available

10.1161/circ.136.suppl_1.20967 Get It

Background: Spontaneous coronary artery dissection (SCAD) is a nonatherosclerotic cause of myocardial infarction (MI) occurring most often in young women without cardiovascular disease (CVD) risk factors. SCAD is associated with fibromuscular dysplasia (FMD), pregnant/postpartum state, and extreme mental stress or physical exertion. Migraine headaches have been reported common in SCAD and may increase CVD risk. The objective was to assess differences in presentation, clinical factors, and outcomes in SCAD patients with migraines (M-SCAD) compared to those without, and determine M-SCAD prevalence. Methods: A retrospective cross-sectional observation study of patients with angiographically confirmed SCAD was conducted using the Mayo Clinic SCAD Registry. Participant-provided data and records were reviewed for migraine history, CVD risk factors, SCAD details, CVD and migraine therapies, and outcomes. Ordinal and nominal variables were compared using Pearson's chi squared test, and continuous variables were compared using Student's t-test. Statistical significance was set at p < 0.05. Results: Among 586 patients with complete questionnaires, 236 had a history of migraines; the lifetime and 1-year prevalence of migraines were 40% and 27% respectively. Migraines are more common in SCAD survivors than a comparable population (40% vs 33%, p=0.0002). M-SCAD patients were more likely to be female (99.6% vs 94%, p=0.001), have SCAD at a younger age (45.3 yrs. vs 47.6 yrs., p=0.004), and report a history of aneurysms (7.6% vs 1.7%, p=0.0004), 46% of which occurred in head or neck vessels. There was a trend toward increased head and neck FMD in M-SCAD (32% vs 23%, p=0.095). Prevalence of depression (27% vs 17%, p=0.005), anxiety (32% vs 24%, p=0.038), recurrent angina (62% vs 44%, p=<0.001) and concern for recurrent SCAD (46% vs 37%, p=0.034) were higher in M-SCAD. Triptans were stopped in 39% of migraineurs at the time of MI. Conclusion: As compared to SCAD survivors without migraines, those with M-SCAD are younger, more often report a history of depression, anxiety, and aneurysms, and have more chest pain after SCAD. Further investigation into this association and development of safe, effective treatments of both headache and angina after SCAD is needed.
Abstract P123: Lipid-lowering Therapy Prescription Patterns and Predictors of High Intensity Statin Prescriptions in Patients With Diabetes or Atherosclerotic Cardiovascular Disease
Killian, Jill M. , Monda, Keri L., Hedgeman, Elizabeth , Weston, Susan A., Okerson, Ted, Chamberlain, Alanna M. , Cohen, Sarah S.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 135 | Issue: suppl_1 | Pages: No page available

10.1161/circ.135.suppl_1.p123 Get It

Background: Many patients with atherosclerotic cardiovascular disease (ASCVD) or diabetes mellitus (DM) do not receive guideline-recommended lipid lowering therapy (LLT). We characterized LLT treatment patterns and identified predictors of high intensity statin prescriptions (Rx) in patients with ASCVD and DM. Methods: Olmsted County, MN residents with DM or ASCVD (MI, unstable angina, revascularization, ischemic stroke/TIA) from 2005-2012 were followed for 2 years capturing all LDL-C and LLT Rx. Cox regression examined predictors of high intensity statin Rx, modeling LDL-C as a time-dependent variable. Results: 8408 patients with DM (n=4881) or ASCVD (n=3527) were identified (mean age 63.1, 55.1% male). Over 2 years, mean (SD) number of LDL-C measurements was 2.7 (1.9); 12.1% had none. Among those with ≥1 LDL-C, the first was ≥100 mg/dL in 46.2%. LLT Rx increased within 30 days after the first LDL-C. (Table). However, among those with LDL-C ≥100, 40.1% were not prescribed LLT; these patients were younger (mean age 56.9 vs 60.8), more likely female (52.7% vs 45.6%) and more likely to have DM vs ASCVD (84.5% vs 54.6%) than those prescribed LLT. High intensity statin Rx increased more for those with LDL-C ≥100 than those with LDL-C <100. Men [HR 1.29 (CI 1.13-1.48)] and patients with ASCVD vs DM [6.12 (5.25-7.12)] were more likely to be prescribed high intensity statins. Higher LDL-C was associated with greater high intensity statin Rx, although associations differed between ASCVD and DM (p-interaction=0.004). Compared to DM, ASCVD patients were more likely prescribed high intensity statins at every level of LDL-C [2.73 (1.70-4.37), 6.47 (4.94-8.47), 5.68 (4.45-7.25), and 7.88 (5.89-10.53) for LDL-C <70, 70-99, 100-130, and ≥130]. Conclusions: Although high intensity statin Rx increased in response to increasing LDL-C, a large proportion of patients do not receive guideline-concordant care. Efforts should be made to encourage more aggressive treatment of elevated LDL-C and to understand why treatment is neglected or delayed.
Abstract 18767: Race-related Disparities in Ventricular-arterial Coupling in Elderly Individuals: The Atherosclerosis Risk in Communities Study
Fernandes-Silva, Miguel Morita , Claggett, Brian , Solomon, Scott D. , Shah, Amil M. , Hegde, Sheila M. , Gonçalves, Alexandra , Cheng, Susan , Nadruz, Wilson , Lam, Carolyn S.P. , Borlaug, Barry A. , Solomon, Scott David

Mayo Clinic

Circulation | March 19, 2022 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.18767 Get It

Introduction: The incidence of heart failure (HF) is higher in black than in white Americans, but the causes are unclear. We proposed that ethnic differences in ventricular-arterial interaction may contribute to this differential HF risk. Methods: We studied measures of arterial elastance (Ea) and left ventricle (LV) end-systolic elastance (Ees) in 5767 community-based elderly participants (76±5 years, 41% male, 22% black) who underwent echocardiography in the Atherosclerosis Risk in Community (ARIC) Study. Results: Black participants were more frequently women (66 vs 57%) and had a higher prevalence of obesity (46 vs 31%), hypertension (94 vs 80%), and diabetes mellitus (47 vs 34%). Adjusting for these baseline differences, the prevalence of LV hypertrophy was similar, but Ea, Ees and Ea/Ees ratio were higher in blacks than whites, particularly in black women (Figure). Ea was positively associated with LV mass index and E/e’ ratio in blacks, but not in whites (p for interaction < 0.001). Conclusion: These community-based data demonstrate that ventricular-arterial stiffening is greater in black than white Americans, coupled with more ventricular remodeling and dysfunction. The heightened afterload dependence in blacks suggests greater potential for risk reduction with anti-hypertensive therapy.
Abstract 45: Characterization of a Novel Integrin Binding Protein that is Essential for αIIbβ3 Outside-in Signaling and Hemostasis
Xiang, Binggang, Zhang, Guoying , Ye, Shaojing , Huang, Cai , Tao, Min , Ruan, Changgeng , Smyth, Susan S. , Li, Zhenyu , Liu, Jun , Whiteheart, Sidney W.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | March 19, 2022 | Volume: 35 | Issue: suppl_1 | Pages: No page available

10.1161/atvb.35.suppl_1.45 Get It

Integrins are heterodimeric (α/β) membrane proteins that play fundamental roles in many biological processes, e.g. cell adhesion and spreading, which are important for platelet function and hemostasis. Integrin function is modulated by bi-directional transmembrane signaling: inside-out and outside-in, which is mediated through the interactions between integrin cytoplasmic tails and intracellular, regulatory proteins. Here, we show that VPS33B, a member of the Sec1/Munc18 (SM) family and component of the Class C core of the CORVET/HOPS sorting complexes, binds directly to the β subunit. Overexpression of VPS33B in CHO cells potentiated α IIb β 3 outside-in signaling but not inside-out signaling. Platelets, from megakaryocyte- and platelet-specific VPS33B conditional knockout mice we generated, had normal morphology yet their spreading on fibrinogen was impaired and they failed to support clot retraction. Platelet aggregation and ATP secretion in response to low-dose thrombin were reduced in the VPS33B knockout mice. α IIb β 3 -mediated endocytosis of fibrinogen was also defective. Tail bleeding times were prolonged in the VPS33B knockout mice. Furthermore, VPS33B acted upstream of the RhoA-ROCK-MLC and Rac1 dependent pathways that leads to clot retraction and cell spreading, respectively. Our work demonstrates that vesicular trafficking complexes are a novel class of modifiers of integrin function and in hemostasis. Our data also provide insights into the molecular mechanism and treatment of ARC syndrome.
Alzheimer's disease and related dementias and heart failure: A community study
Manemann, Sheila M., Weston, Susan A., Jiang, Ruoxiang , Roger, Véronique L. , St Sauver, Jennifer, Bielinski, Suzette J. , Knopman, David S. , Sauver, Jennifer L. St. , Chamberlain, Alanna M.

Mayo Clinic

Journal of the American Geriatrics Society | March 19, 2022 | Volume: 70 | Issue: 6 | Pages: 1664-1672

10.1111/jgs.17752 | PMID 35304739 Get It

Abstract Background Cognitive function is essential to effective self‐management of heart failure (HF). Alzheimer's disease and Alzheimer's disease‐related dementias (AD/ADRD) can coexist with HF, but its exact prevalence and impact on health care utilization and death are not well defined. Methods Residents from 7 southeast Minnesota counties with a first‐ever diagnosis code for HF between January 1, 2013 and December 31, 2018 were identified. Clinically diagnosed AD/ADRD was ascertained using the Centers for Medicare and Medicaid (CMS) Chronic Conditions Data Warehouse algorithm. Patients were followed through March 31, 2020. Cox and Andersen‐Gill models were used to examine associations between AD/ADRD (before and after HF) and death and hospitalizations, respectively. Results Among 6336 patients with HF (mean age [SD] 75 years [14], 48% female), 644 (10%) carried a diagnosis of AD/ADRD at index HF diagnosis. The 3‐year cumulative incidence of AD/ADRD after HF diagnosis was 17%. During follow‐up (mean [SD] 3.2 [1.9] years), 2618 deaths and 15,475 hospitalizations occurred. After adjustment, patients with AD/ADRD before HF had nearly a 2.7 times increased risk of death, but no increased risk of hospitalization compared to those without AD/ADRD. When AD/ADRD was diagnosed after the index HF date, patients experienced a 3.7 times increased risk of death and a 73% increased risk of hospitalization compared to those who remain free of AD/ADRD. Conclusions In a large, community cohort of patients with incident HF, the burden of AD/ADRD is quite high as more than one‐fourth of patients with HF received a diagnosis of AD/ADRD either before or after HF diagnosis. AD/ADRD markedly increases the risk of adverse outcomes in HF underscoring the need for future studies focused on holistic approaches to improve outcomes.
Inherited genetics of adult diffuse glioma and polygenic risk scores—a review
Eckel‐Passow, Jeanette E. , Decker, Paul A. , Kollmeyer, Thomas M. , Kosel, Matthew , Wrensch, Margaret , Tobin, W. Oliver , Jenkins, Robert B. , Drucker, Kristen L, Slager, Susan, Jenkins, RB , Kollmeyer, Thomas , Tobin, W Oliver , Lachance, Daniel Honore , Decker, Paul A. , Drucker, Kristen , Slager, Susan L.

Mayo Clinic

Neuro-Oncology Practice | March 12, 2022 | Volume: 9 | Issue: 4 | Pages: 259-270

10.1093/nop/npac017 | PMID 35859544 Get It

Abstract Knowledge about inherited and acquired genetics of adult diffuse glioma has expanded significantly over the past decade. Genomewide association studies (GWAS) stratified by histologic subtype identified six germline variants that were associated specifically with glioblastoma (GBM) and 12 that were associated with lower grade glioma. A GWAS performed using the 2016 WHO criteria, stratifying patients by IDH mutation and 1p/19q codeletion (as well as TERT promoter mutation), discovered that many of the known variants are associated with specific WHO glioma subtypes. In addition, the GWAS stratified by molecular group identified two additional novel regions: variants in D2HGDH that were associated with tumors that had an IDH mutation and a variant near FAM20C that was associated with tumors that had both IDH mutation and 1p/19q codeletion. The results of these germline associations have been used to calculate polygenic risk scores, from which to estimate relative and absolute risk of overall glioma and risk of specific glioma subtypes. We will review the concept of polygenic risk models and their potential clinical utility, as well as discuss the published adult diffuse glioma polygenic risk models. To date, these prior genetic studies have been done on European populations. Using the published glioma polygenic risk model, we show that the genetic associations published to date do not generalize across genetic ancestries, demonstrating that genetic studies need to be done on more diverse populations.
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
Gillison, Maura L. , Maghami, Ellie, Spencer, Sharon, Pfister, David G. , Birkeland, Andrew C. , Busse, Paul M., Cmelak, Anthony J. , Eisele, David W. , Galloway, Thomas J. , Geiger, J.L. , Haddad, Robert I. , Hicks, Wesley L. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Mell, Loren K. , Mittal, Bharat B. , Pinto, Harlan A. , Rocco, James W. , Rodriguez, Cristina P. , Savvides, P. , Sher, David J. , Weber, Randal S. , Weinstein, Gregory S., Worden, Frank , Yom, Sue S. , Zhen, Weining, Burns, Jennifer L. , Darlow, Susan, Savvides, Panayiotis S, Haddad, Robert , Mittal, Bharat B , Yom, Sue S , Caudell, Jimmy J , Adkins, Douglas R. , Brizel, David M. , Colevas, Alexander Dimitrios , Schwartz, David A. , Shah, Jatin P. , John, Maie A. St. , Bruce, Justine Y.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 11, 2022 | Volume: 20 | Issue: 3 | Pages: 224-234

10.6004/jnccn.2022.0016 | PMID 35276673 Get It

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer, salivary gland cancer, and mucosal melanoma (MM) are also addressed. The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of HPV-positive oropharynx cancer and ongoing research in this area.
Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Potter, David A. , Roesch, Erin , Lu, Ruixiao , Samson, Susan, Stafford, Debra, Albain, Kathy S. , Chien, A. Jo , Perlmutter, Jane , Melisko, Michelle , Veer, Laura van ‘t , Wilson, Amy , Asare, Smita , Berry, Donald A. , Schwab, Richard B. , Potter, David A , Yau, Christina , Wolf, Denise M. , Isaacs, Claudine , Trivedi, Meghana V. , Yee, Douglas , Boughey, Judy C. , Thomas, Alexandra , Hylton, Nola M. , Li, Wen , DeMichele, Angela , Symmans, W. Fraser , Hershman, Dawn L. , Veer, Laura J. van’t , Rugo, Hope S. , Esserman, Laura J.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: PD8-07-PD8-07

10.1158/1538-7445.sabcs21-pd8-07 Get It

Abstract Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk breast cancer. Tucatinib is a potent HER2 (ErbB2) tyrosine kinase inhibitor, selective for HER2 vs. epidermal growth factor receptor (EGFR) and is active vs. brain metastases. Safety and efficacy of tucatinib combined with paclitaxel, pertuzumab, and trastuzumab are unknown and were tested in a planned 10 patient (pt) safety run-in of the I-SPY 2 trial. Methods: Women with tumors ≥ 2.5cm were eligible for screening. Only pts with tumors that were HER2+ by FISH were eligible for this treatment. Treatment included tucatinib (max dose 300 mg) BID for 12 weeks with weekly paclitaxel 80 mg/m2 and trastuzumab (2 mg/kg weekly following loading), and pertuzumab (420 mg every 3 weeks following loading), followed by doxorubicin/cyclophosphamide (AC) every 2 weeks x 4. The control arm was weekly paclitaxel and trastuzumab with pertuzumab for 12 weeks followed by AC every 2 weeks x 4. All pts undergo serial MR imaging and response at 3 & 12 weeks is combined with real time pCR data to estimate, and continuously update, the predicted pCR rate for each trial arm. The goal of the trial is to identify/graduate regimens with ≥85.% Bayesian predictive probability of success (i.e. demonstrating superiority to control) in a future 300-patient phase 3 neoadjuvant trial with a pCR endpoint. This run-in arm was conducted to determine safety of combining tucatinib with paclitaxel/trastuzumab/pertuzumab, monitoring special adverse events of interest including LFT elevations and gastrointestinal toxicities.Methods: The I-SPY 2 methods have been previously published. Results: 20 pts were evaluable in tucatinib treatment arm. The control arm included 329 historical controls enrolled since April 2010. The initial tucatinib dose was 300 mg BID. After enrollment of the first 8 pts, there were 3 pts with grade 3 LFT elevations, 2 pts with grade 2/3 diarrhea, 1 pt with grade 2 neutropenia, and 1 pt with grade 3 nausea. After this safety review, the tucatinib dose was lowered to 250 mg BID. Among 5 additional pts enrolled, 3 developed grade 2/3 LFT abnormalities. The protocol was then modified to tucatinib 150 mg BID days 1-28 and then 250 mg BID days 29-84; 7 pts were treated. Safety data were reviewed after 20 pts were enrolled; the arm was then suspended due to similar LFT elevations regardless of tucatinib dose reduction or schedule. 7 of 20 pts (35%) had reversible Grade 3 or higher ALT/AST elevation (Table). No pt met criteria for Hy’s Law. In terms of efficacy, 12 of 14 evaluable pts had &gt; 80% reduction of tumor volume by 12 weeks, measured by MRI assessment of functional tumor volume (FTV). Conclusion: The goal of the run-in arm was to determine the safety of adding tucatinib to the combination of paclitaxel/trastuzumab/pertuzumab. The addition of tucatinib resulted in unacceptable but reversible LFT elevations despite tucatinib dose reduction. Tucatinib containing therapy resulted in &gt;80% decline in tumor volume at 12 weeks in 86% of pts. Tucatinib showed a high level of activity when combined with paclitaxel/trastuzumab/pertuzumab, but the combination is not feasible. Table: Number of pts with grade 2, 3, and 4 LFT elevations by treatment schedule (highest grade per patient per event, ALT or Treatment scheduleGrade 2 LFT elevationGrade 3 LFT elevationGrade 4 LFT elevationTucatinib 300 mg BID030Tucatinib 250 mg BID210Tucatinib 150 mg BID days 1-28 followed by 250 mg BID days 29 to 84112 Citation Format: David A Potter, Erin Roesch, Christina Yau, Ruixiao Lu, Denise Wolf, Susan Samson, Debra Stafford, Kathy S Albain, Claudine Isaacs, Meghana Trivedi, Douglas Yee, Judy Boughey, Alexandra Thomas, A. Jo Chien, Nola Hylton, Wen Li, Angela DeMichele, Jane Perlmutter, W. Fraser Symmans, Dawn L Hershman, Michelle Melisko, Laura J van 't Veer, Amy Wilson, Smita M Asare, Donald A Berry, Richard Schwab, Hope S Rugo, Laura J Esserman. Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD8-07.
Abstract P4-12-02: Improving patient-reported outcome data capture for clinical research: ePRO in ISPY 2, a phase 2 breast cancer study
Northrop, Anna, Christofferson, Anika, Melisko, Michelle , Sit, Laura , Olunuga, Ebunoluwa , Mittal, Ananya , Goldman, Adi, Brown, Thelma, Heditsian, Diane , Parker, Bev, Brain, Susie, Simmons, Carol A., Taboada, Alessandra, Ruddy, Kathryn J. , Salvador, Carolina, Afghahi, Anosheh , Tevis, Sarah , Melin, Susan A., Simmons, Carol, Hieken, Tina J. , Piltin, Mara A. , Cook, Kiri A. , Salvador, Carolina, Mainor, Candace , Blaes, Anne , Kang, Irene , Esserman, Laura J. , Asare, Adam L. , Hershman, Dawn L. , Basu, Amrita B

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: P4-12-02-P4-12-02

10.1158/1538-7445.sabcs21-p4-12-02 Get It

Abstract Introduction: Advances in technology and internet capability have provided an opportunity for efficient collection of Patient Reported Outcomes (PRO) during medical treatment. Here we describe the development and implementation of a system for monitoring patient reported adverse events (AEs) and quality of life (QoL) using electronic PRO (ePRO) instruments for patients enrolled on the Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis (I-SPY 2 TRIAL), a phase II adaptive platform clinical trial for locally advanced breast cancer. Methods: We designed an ePRO system to increase the accuracy of patient-reported QoL and AE data collection with the intent to act on symptoms in real time. Using the OpenClinica electronic data capture system, we developed rules-based logic to build automated ePRO surveys, customized to the I-SPY 2 treatment schedule. Weekly surveys contained a maximum of 126 validated, branching logic questions from the Patient Reported Outcomes Measurement Information System (PROMIS®) Health Measures and the National Cancer Institute’s Patient Reported Outcomes - Common Terminology Criteria for Adverse Events (PRO-CTCAE™) instruments. We piloted ePROs at the University of California, San Francisco (UCSF) to evaluate compatibility with a variety of I-SPY 2 patient scenarios (e.g., dose delays). We then staggered rollout of the ePRO system to 22 I-SPY 2 sites to ensure technological feasibility. In order to improve accuracy of data collection, we utilized real-time tracking and developed a Clinical Research Coordinator (CRC) training manual, which integrated workflow diagrams with technical solutions. CRCs were trained using remote video sessions. Results: The UCSF ePRO pilot began in September of 2020. Over 9-months, we accrued 43 I-SPY 2 patients (average age of 43.8 years), whose interactions with the ePRO system informed design improvements. Of the patients who received a baseline ePRO survey, the completion rate was 75.9% (average age of 44.2 years). This represents an increase from the 15-20% baseline completion rate for the 360 UCSF I-SPY 2 patients who received paper-based PRO surveys between May 2012 - January 2019. As of June 2021, the ePRO system was operational at all 22 I-SPY 2 sites. The UCSF pilot revealed that engagement with patients at critical timepoints improved survey completion. CRCs facilitated patient participation by sending instructional emails and communicating with patients weekly. We tracked data completeness using a Patient Tracking report, which displayed each patient’s survey completion history. This real-time tool enabled CRCs to identify patients who had not completed ePRO surveys prior to their visit, so they could be provided a tablet computer to complete the survey in the clinic. After introducing tablets into the workflow at UCSF, patient completion of the baseline survey increased from 75.9% to 80%. Conclusion: The transition from paper to electronic QOL and AE data collection improves the ability of patients to complete PRO surveys, but the process must also be optimized and integrated into clinical workflow and trial conduct. In the future, we will present additional results highlighting the feasibility of multilingual ePRO integration into I-SPY 2. ePRO also provides a new opportunity for data analysis, as well as the potential to reduce high grade toxicity through early intervention. It will allow us to assess QoL and AE data by drug regimen, site, provider, and study treatment. The creation of clinician-facing reports also enables access to patient responses in real-time. By implementing ePRO within I-SPY 2, we not only increase efficiency and accuracy of patient-reported data collection, but also improve quality of care and patient safety. Citation Format: Anna Northrop, Anika Christofferson, Michelle Melisko, Laura Sit, Ebunoluwa Olunuga, Ananya Mittal, Adi Goldman, Thelma Brown, Diane Heditsian, Bev Parker, Susie Brain, Carol Simmons, Alessandra Taboada, Kathryn J Ruddy, Tina Hieken, Mara Piltin, Kiri Cook, Carolina Salvador, Candace Mainor, Anosheh Afghahi, Sarah Tevis, Anne Blaes, Irene Kang, Susan Melin, Laura Esserman, Adam Asare, Dawn L Hershman, Amrita Basu. Improving patient-reported outcome data capture for clinical research: ePRO in ISPY 2, a phase 2 breast cancer study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-12-02.
Abstract P2-09-01: Population-based risk estimates of clinical subtypes of breast cancer among carriers of germline pathogenic variants in cancer predisposition genes
Yadav, Siddhartha , Huang, Hongyan , Yao, Song, Vachon, Celine M. , Martínez, Elena, Lindströem, Sara, Haiman, Christopher A. , Gaudet, Mia M. , Auer, Paul, Goldgar, David E. , Nathanson, Katherine L. , Yadav, Siddhartha , Nathanson, Katherine L , Hu, Chunling , Boddicker, Nicholas , Polley, Eric C. , Hart, Steven N. , Gnanaolivu, Rohan , Na, Jie , Yao, Song , Vachon, Celine M. , Teras, Lauren R. , Taylor, Jack A. , Sandler, Dale P. , Palmer, Julie R. , Olson, Janet E. , Neuhausen, Susan L. , Marchand, Loı̈c Le , Kooperberg, Charles , Lacey, James V. , Bertrand, Kimberly A. , Bernstein, Leslie , Ambrosone, Christine B. , Weitzel, Jeffrey N. , Kraft, Peter , Domchek, Susan M. , Couch, Fergus J.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: P2-09-01-P2-09-01

10.1158/1538-7445.sabcs21-p2-09-01 Get It

Abstract Introduction: The risk of specific clinical subtype of breast cancer (defined by ER and HER2 status) among women in the general population who are carriers of germline pathogenic variants (PVs) in cancer predisposition genes is not well-defined. Methods: A total of 13,153 women with breast cancer (ER+/HER2-: 9381; ER+/HER2+: 1462; ER-/HER2+: 690; and ER-/HER2-: 1620) and 25,005 unaffected women (controls) from nine studies within the CAnceR RIsk Estimates Related to Susceptibility (CARRIERS) consortium that were not enriched for family history or early onset disease were included in the present analysis. A multiplex amplicon-based panel was used to perform germline sequencing for cancer predisposition genes. Case-control associations for each of the four clinical subtype of breast cancer was performed for PVs in 5 common breast cancer predisposition genes (ATM, BRCA1, BRCA2, CHEK2 and PALB2) utilizing a logistic regression model adjusting for study, age at diagnosis, race/ethnicity and family history of breast cancer. Results: The frequency of PVs in 5 genes was 3.8% for ER+/HER2-, 6.2% for ER+/HER2+, 4.2% for ER-/HER2+ and 9.3% for ER-/HER2- subtypes. PVs in BRCA1 and BRCA2 were associated with high risk (Odds Ratio (OR) &gt;4) for all clinical subtypes of breast cancer, but the risk was highest (OR&gt;8) for ER-/HER2- breast cancer. PVs in PALB2 were associated with high risk (OR&gt;4) of ER-/HER2- and ER+/HER2+ subtypes and moderate risk (OR: 2-4) of ER+/HER2- breast cancer. Irrespective of the HER2 status, PVs in ATM were associated with a moderately increased risk (OR: 2-4) of ER+ breast cancer but the risk of ER- breast cancer was not elevated. In contrast, PVs in CHEK2 were associated with high risk (OR&gt;4) of ER+/HER2+ breast cancer and moderate risk (OR: 2-4) of ER+/HER2- and ER-/HER2+ breast cancer, but the risk of ER-/HER2- breast cancer was not elevated. Conclusions: This study provides population-based estimates of risk of specific clinical subtypes of breast cancer which will be useful for genetic counseling and targeting appropriate screening strategies in PV carriers based on subtype specific risks of breast cancer. Citation Format: Siddhartha Yadav, Chunling Hu, Nicholas J. Boddicker, Eric Polley, Steven Hart, Rohan Gnanaolivu, Jie Na, Hongyan Huang, Song Yao, Celine M. Vachon, Lauren Teras, Jack A. Taylor, Dale P. Sandler, Julie R. Palmer, Janet E. Olson, Susan Neuhausen, Elena Martinez, Sara Lindstroem, Loic Le Marchand, Charles Kooperberg, Christopher Haiman, Mia M. Gaudet, James V. Lacey, Kimberly A. Bertrand, Leslie Bernstein, Paul W. Auer, Christine Ambrosone, Jeffrey N. Weitzel, Peter Kraft, David E. Goldgar, Katherine L. Nathanson, Susan M. Domchek, Fergus J. Couch, CARRIERS Consortium. Population-based risk estimates of clinical subtypes of breast cancer among carriers of germline pathogenic variants in cancer predisposition genes [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-09-01.